181 related articles for article (PubMed ID: 26777537)
1. Outcomes of patients with myelodysplastic syndromes who achieve stable disease after treatment with hypomethylating agents.
Nazha A; Sekeres MA; Garcia-Manero G; Barnard J; Al Ali NH; Roboz GJ; Steensma DP; DeZern AE; Zimmerman C; Jabbour EJ; Zell K; List AF; Kantarjian HM; Maciejewski JP; Komrokji RS;
Leuk Res; 2016 Feb; 41():43-7. PubMed ID: 26777537
[TBL] [Abstract][Full Text] [Related]
2. Treatment with 5-Azacytidine improves clinical outcome in high-risk MDS patients in the 'real life' setting: A single center observational study.
Papageorgiou SG; Vasilatou D; Kontos CK; Foukas P; Kefala M; Ioannidou ED; Bouchla A; Bazani E; Dimitriadis G; Pappa V
Hematology; 2016 Jan; 21(1):34-41. PubMed ID: 26218077
[TBL] [Abstract][Full Text] [Related]
3. Discontinuation of hypomethylating agent therapy in patients with myelodysplastic syndromes or acute myelogenous leukemia in complete remission or partial response: retrospective analysis of survival after long-term follow-up.
Cabrero M; Jabbour E; Ravandi F; Bohannan Z; Pierce S; Kantarjian HM; Garcia-Manero G
Leuk Res; 2015 May; 39(5):520-4. PubMed ID: 25828745
[TBL] [Abstract][Full Text] [Related]
4. Standard dose and prolonged administration of azacitidine are associated with improved efficacy in a real-world group of patients with myelodysplastic syndrome or low blast count acute myeloid leukemia.
Voso MT; Niscola P; Piciocchi A; Fianchi L; Maurillo L; Musto P; Pagano L; Mansueto G; Criscuolo M; Aloe-Spiriti MA; Buccisano F; Venditti A; Tendas A; Piccioni AL; Zini G; Latagliata R; Filardi N; Fragasso A; Fenu S; Breccia M;
Eur J Haematol; 2016 Apr; 96(4):344-51. PubMed ID: 26018238
[TBL] [Abstract][Full Text] [Related]
5. Differential response to hypomethylating agents based on sex: a report on behalf of the MDS Clinical Research Consortium (MDS CRC).
DeZern AE; Zeidan AM; Barnard J; Hand W; Al Ali N; Brown F; Zimmerman C; Roboz GJ; Garcia-Manero G; Steensma DP; Komrokji RS; Sekeres MA;
Leuk Lymphoma; 2017 Jun; 58(6):1325-1331. PubMed ID: 27774847
[TBL] [Abstract][Full Text] [Related]
6. Low-dose 5-aza-2'-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients.
Wijermans P; Lübbert M; Verhoef G; Bosly A; Ravoet C; Andre M; Ferrant A
J Clin Oncol; 2000 Mar; 18(5):956-62. PubMed ID: 10694544
[TBL] [Abstract][Full Text] [Related]
7. Benefits of hypomethylating therapy in IPSS lower-risk myelodysplastic syndrome patients: A retrospective multicenter case series study.
Lee JH; Kim YJ; Sohn SK; Yoon SS; Kim H; Cheong JW; Lee WS; Lee GW; Lim SN; Kim MK; Lee HS; Kim HJ;
Leuk Res; 2017 Sep; 60():135-144. PubMed ID: 28826063
[TBL] [Abstract][Full Text] [Related]
8. Evidence for Selective Benefit of Sequential Treatment With Hypomethylating Agents in Patients With Myelodysplastic Syndrome.
Apuri S; Al Ali N; Padron E; Lancet JE; List AF; Komrokji RS
Clin Lymphoma Myeloma Leuk; 2017 Apr; 17(4):211-214. PubMed ID: 28185797
[TBL] [Abstract][Full Text] [Related]
9. No clear survival benefit of azacitidine for lower-risk myelodysplastic syndromes: A retrospective study of Nagasaki.
Toriyama E; Hata T; Yokota KI; Chiwata M; Kamijo R; Hashimoto M; Taguchi M; Horai M; Matsuo M; Matsuo E; Takasaki Y; Kawaguchi Y; Itonaga H; Sato S; Ando K; Sawayama Y; Taguchi J; Imaizumi Y; Tsushima H; Jo T; Yoshida S; Moriuchi Y; Miyazaki Y
Cancer Sci; 2020 Dec; 111(12):4490-4499. PubMed ID: 32939867
[TBL] [Abstract][Full Text] [Related]
10. Outcome of patients with high risk Myelodysplastic Syndrome (MDS) and advanced Chronic Myelomonocytic Leukemia (CMML) treated with decitabine after azacitidine failure.
Harel S; Cherait A; Berthon C; Willekens C; Park S; Rigal M; Brechignac S; Thépot S; Quesnel B; Gardin C; Adès L; Fenaux P; Braun T
Leuk Res; 2015 May; 39(5):501-4. PubMed ID: 25735917
[TBL] [Abstract][Full Text] [Related]
11. Superiority of prolonged low-dose azanucleoside administration? Results of 5-aza-2'-deoxycytidine retreatment in high-risk myelodysplasia patients.
Rüter B; Wijermans PW; Lübbert M
Cancer; 2006 Apr; 106(8):1744-50. PubMed ID: 16532502
[TBL] [Abstract][Full Text] [Related]
12. Use of hypomethylating agents and associated care in patients with myelodysplastic syndromes: a claims database study.
Hatoum HT; Lin SJ; Buchner D; Kim E
Curr Med Res Opin; 2011 Jun; 27(6):1255-62. PubMed ID: 21554144
[TBL] [Abstract][Full Text] [Related]
13. Outcome of patients with low-risk and intermediate-1-risk myelodysplastic syndrome after hypomethylating agent failure: a report on behalf of the MDS Clinical Research Consortium.
Jabbour EJ; Garcia-Manero G; Strati P; Mishra A; Al Ali NH; Padron E; Lancet J; Kadia T; Daver N; O'Brien S; Steensma DP; Sekeres MA; Gore SD; Dezern A; Roboz GJ; List AF; Kantarjian HM; Komrokji RS
Cancer; 2015 Mar; 121(6):876-82. PubMed ID: 25410759
[TBL] [Abstract][Full Text] [Related]
14. Cytogenetic response based on revised IPSS cytogenetic risk stratification and minimal residual disease monitoring by FISH in MDS patients treated with low-dose decitabine.
Li X; Chang C; He Q; Xu F; Zhang Q; Wu L; Su J; Zhang X; Zhou L; Wu D; Song L; Zhang Z
Leuk Res; 2013 Nov; 37(11):1516-21. PubMed ID: 24084368
[TBL] [Abstract][Full Text] [Related]
15. Comparative clinical effectiveness of azacitidine versus decitabine in older patients with myelodysplastic syndromes.
Zeidan AM; Davidoff AJ; Long JB; Hu X; Wang R; Ma X; Gross CP; Abel GA; Huntington SF; Podoltsev NA; Hajime U; Prebet T; Gore SD
Br J Haematol; 2016 Dec; 175(5):829-840. PubMed ID: 27650975
[TBL] [Abstract][Full Text] [Related]
16. [Decitabine treatment in myelodysplastic syndromes--results of a compassionate patient program in Israel].
Klepfish A; Silbershatz I; Lugassy G; Shimoni A; Mittelman M
Harefuah; 2013 Oct; 152(10):591-4, 624. PubMed ID: 24450031
[TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of azacitidine in Belgian patients with high-risk myelodysplastic syndromes, acute myeloid leukaemia, or chronic myelomonocytic leukaemia: results of a real-life, non-interventional post-marketing survey.
Beguin Y; Selleslag D; Meers S; Graux C; Bries G; Deeren D; Vrelust I; Ravoet C; Theunissen K; Voelter V; Potier H; Trullemans F; Noens L; Mineur P
Acta Clin Belg; 2015 Feb; 70(1):34-43. PubMed ID: 25444072
[TBL] [Abstract][Full Text] [Related]
18. The outcome of patients with high-risk MDS achieving stable disease after treatment with 5-azacytidine: A retrospective analysis of the Hellenic (Greek) MDS Study Group.
Papageorgiou SG; Kontos CK; Kotsianidis I; Vasilatou D; Symeonidis A; Galanopoulos A; Bouchla A; Hatzimichael E; Repousis P; Zikos P; Viniou NA; Poulakidas E; Vassilakopoulos TP; Diamantopoulos P; Diamantopoulos MA; Mparmparousi D; Bouronikou E; Papadaki H; Panayiotidis P; Pappa V
Hematol Oncol; 2018 Oct; 36(4):693-700. PubMed ID: 30129144
[TBL] [Abstract][Full Text] [Related]
19. Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome.
Kantarjian HM; O'Brien S; Shan J; Aribi A; Garcia-Manero G; Jabbour E; Ravandi F; Cortes J; Davisson J; Issa JP
Cancer; 2007 Jan; 109(2):265-73. PubMed ID: 17133405
[TBL] [Abstract][Full Text] [Related]
20. Report on outcomes of hypomethylating therapy for analyzing prognostic value of Revised International Prognostic Scoring System for patients with lower-risk myelodysplastic syndromes.
Lee YJ; Park SW; Lee IH; Ahn JS; Kim HJ; Chung JS; Shin HJ; Lee WS; Lee SM; Joo YD; Kim H; Lee HS; Kim YS; Cho YY; Moon JH; Sohn SK
Ann Hematol; 2016 Oct; 95(11):1795-804. PubMed ID: 27530461
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
